Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An analysis ...

Pfizer Ltd has announced that the Scottish Medicines Consortium (SMC) has accepted Talzenna (talazoparib) in combination with ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR) gene alterations, talazoparib (TALA) + enzalutamide (ENZA ...

Two new drugs to treat prostate and liver cancer have been given the green light for use by the NHS in Scotland. The Scottish ...

Several authors disclosed ties to Pfizer, which manufactures talazoparib. Abstract More Information ...

Two new medicines have been approved to help treat prostate and liver cancer patients in Scotland. The Scottish Medicines ...

Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in ...

Talazoparib (known under the brand name Talzenna), used together with enzalutamide, was accepted for the treatment of adults with prostate cancer. Its approval has been praised for offering ...

TWO drugs to treat patients with liver and advanced prostate cancer were yesterday approved for Scotland’s NHS. Experts hailed the news as an “important step forward” for those who have already ...